Defence Provides Update on Delivery of AGSM Proxy Materials
Defence Therapeutics announces its annual general and special meeting of shareholders scheduled for December 12th, 2024, at 10:00 a.m. (Pacific Time) in Vancouver. Shareholders of record as of November 4, 2024, are eligible to vote, with a proxy deadline of December 10th, 2024, at 10:00 a.m. Due to a Canada Post labour strike, shareholders may experience delays in receiving the Information Circular dated November 8, 2024. The company encourages shareholders to access materials electronically via SEDAR+ and vote according to the Circular's instructions.
Defence Therapeutics annuncia la sua assemblea generale e speciale annuale degli azionisti, prevista per il 12 dicembre 2024, alle 10:00 (ora del Pacifico) a Vancouver. Gli azionisti registrati al 4 novembre 2024 sono idonei a votare, con una scadenza per la delega fissata al 10 dicembre 2024, alle 10:00. A causa di uno sciopero dei lavoratori di Canada Post, gli azionisti potrebbero subire ritardi nella ricezione del Circular Informativo datato 8 novembre 2024. La societ脿 invita gli azionisti a accedere ai materiali elettronicamente tramite SEDAR+ e a votare secondo le istruzioni del Circular.
Defence Therapeutics anuncia su reuni贸n general y especial anual de accionistas programada para el 12 de diciembre de 2024, a las 10:00 a.m. (Hora del Pac铆fico) en Vancouver. Los accionistas registrados a partir del 4 de noviembre de 2024 son elegibles para votar, con una fecha l铆mite para la delegaci贸n establecida para el 10 de diciembre de 2024, a las 10:00 a.m. Debido a una huelga laboral de Canada Post, los accionistas pueden experimentar retrasos en la recepci贸n del Circular de Informaci贸n con fecha del 8 de noviembre de 2024. La empresa anima a los accionistas a acceder a los materiales electr贸nicamente a trav茅s de SEDAR+ y a votar de acuerdo con las instrucciones del Circular.
Defense Therapeutics電� 2024雲� 12鞗� 12鞚� 鞓れ爠 10鞁�(韮滍弶鞏� 響滌鞁�)鞐� 氚挫繝氩勳棎靹� 鞐措Υ 欤检＜ 齑濏殞 氚� 韸闺硠 須岇潣毳� 氚滍憸頄堨姷雼堧嫟. 2024雲� 11鞗� 4鞚� 旮办鞙茧 霌彪霅� 欤检＜電� 韴憸 鞛愱博鞚� 鞛堨溂氅�, 鞙勳瀯鞛� 鞝滌稖 毵堦皭鞚检潃 2024雲� 12鞗� 10鞚� 鞓れ爠 10鞁滌瀰雼堧嫟. 旌愲倶雼� 瓿奠偓 韺岇梾鞙茧 鞚疙暣 欤检＜霌れ潃 2024雲� 11鞗� 8鞚检瀽 鞝曤炒 靹滌嫚鞚� 氚涬姅 雿� 歆�鞐办潉 瓴潉 靾� 鞛堨姷雼堧嫟. 須岇偓電� 欤检＜霌れ棎瓴� SEDAR+毳� 韱淀暣 鞝勳瀽鞝侅溂搿� 鞛愲鞐� 鞝戧芳頃橁碃 靹滌嫚鞚� 歆�旃棎 霐半澕 韴憸頃� 瓴冹潉 甓岇灔頃╇媹雼�.
Defence Therapeutics annonce sa r茅union g茅n茅rale annuelle et sp茅ciale des actionnaires pr茅vue pour le 12 d茅cembre 2024 脿 10h00 (heure du Pacifique) 脿 Vancouver. Les actionnaires enregistr茅s au 4 novembre 2024 sont 茅ligibles pour voter, avec une date limite de procuration fix茅e au 10 d茅cembre 2024 脿 10h00. En raison d'une gr猫ve des travailleurs de Canada Post, les actionnaires peuvent conna卯tre des retards dans la r茅ception du Circulaire d'Information dat茅e du 8 novembre 2024. La soci茅t茅 encourage les actionnaires 脿 acc茅der aux documents 茅lectroniquement via SEDAR+ et 脿 voter selon les instructions du Circulaire.
Defence Therapeutics k眉ndigt seine j盲hrliche Haupt- und Sonderversammlung der Aktion盲re an, die f眉r den 12. Dezember 2024 um 10:00 Uhr (Pazifische Zeit) in Vancouver geplant ist. Aktion盲re, die am 4. November 2024 registriert sind, sind wahlberechtigt, wobei die Frist f眉r eine Vollmacht am 10. Dezember 2024 um 10:00 Uhr endet. Aufgrund eines Arbeitsstreiks bei Canada Post k枚nnen Aktion盲re Verz枚gerungen beim Erhalt des Informationsrundschreibens vom 8. November 2024 erfahren. Das Unternehmen ermutigt die Aktion盲re, die Unterlagen elektronisch 眉ber SEDAR+ abzurufen und gem盲脽 den Anweisungen des Rundschreibens zu w盲hlen.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is to hold its annual general and special meeting of the shareholders (the "Shareholders") of the Company on December 12th, 2024 at 10:00 a.m. (Pacific Time) at the office of McMillan LLP located at Royal Center, 1055 W. Georgia Street, Suite 1500, Vancouver, British Columbia (the "Meeting").
The Shareholders of record as of the close of business on November 4, 2024, are entitled to receive notice of and to vote at the Meeting. The Shareholders are urged to vote before the proxy deadline of 10:00 a.m. on December 10th, 2024.
The Information Circular of the Company dated November 8, 2024 (the "Circular") provides important information on the matters to be approved by the Shareholders at the Meeting and voting procedures. The Circular is being delivered to the Shareholders in compliance with applicable Canadian securities laws and available under the Company's profile on SEDAR+ at .
Due to the ongoing Canada Post labour strike, the Shareholders may experience a delay in receiving the Circular and related materials in respect of the Meeting. All Shareholders are encouraged to access the Circular and related materials electronically and to vote in accordance with the instructions set forth in the Circular. Registered shareholders should complete all signed proxy forms as directed on the form of proxy no later than 48 hours prior to the Meeting. Beneficial owners can obtain a copy of the voting instructions form from their intermediary.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
FAQ
When is Defence Therapeutics (DTCFF) holding its 2024 annual general meeting?
What is the voting deadline for Defence Therapeutics (DTCFF) 2024 annual meeting?
How can shareholders access Defence Therapeutics (DTCFF) meeting materials during the Canada Post strike?
What is the record date for Defence Therapeutics (DTCFF) 2024 annual meeting?
